



> Returnaddress P.O. Box 30945 2500 GX The Hague

Commissariat à l' énergie atomique  
Alain Aberman  
Responsable projets commerciaux  
Centre de Saclay- DEN/DANS/DRSN- Bât.526  
91191 Gif-sur-Yvette Cedex  
France

Date February 2, 2009  
Subject request of information

**Directoraat-Generaal  
Milieu**

Directie Risicobeleid  
Straling, Nucleaire en  
Bioveiligheid

Rijnstraat 8  
P.O. Box 30945  
2500 GX The Hague  
Internal Postal Code 645  
The Netherlands  
www.vrom.nl

**Contactperson**

Dr. M.G. Delfini

T +31 (0)70 339 49 66  
F +31 (0)70 339 12 86

**Our reference**

RB/2009010009

Dear mister Alberman,

As you know in these days the Dutch government is discussing the possibility of allowing the operation of the HFR reactor in Petten, in view of the worldwide need of radioisotopes for nuclear medicine. The decision takes into account on the one hand the fact that corrosion has been detected in the primary cooling system of the HFR reactor, and on the other hand the fact that isotopes production is necessary for diagnostic and therapeutic procedures in nuclear medicine.

During the discussion last friday more information was asked about the possibilities to produce isotopes in the other european reactors, the BR2 in Belgium and the OSIRIS in France. This is the reason why I am turning to you as commercial and project manager at the OSIRIS reactor in Saclay.  
In order to provide the government with the information they asked for, I would appreciate if you could answer the following questions:


- 1) Where there actions taken at the OSIRIS reactor during the last months (since august 2008) in order to help compensate for the lack of isotopes production following the shut down of the HFR reactor in Petten? What actions were taken?
- 2) Was the scheduling of the isotopes irradiation in the OSIRIS reactor modified with respect to previous planning? Could you give more detail information about that?
- 3) Would it be possible to arrange the scheduling of the isotopes irradiation in the coming months (until the end of 2009) in such a way that lack of production in HFR is compensated for? If not, could you give some information as to the reasons of that? Are there legal, technical or commercial reasons that prevent increased isotope production at OSIRIS?

The discussion in the Dutch government is foreseen for coming friday. In view of that I would appreciate if you could answer within a couple of days (wednesday at the latest). I do apologize for the very short notice and I thank you in advance for your cooperation.

If you have any question of if you need clarification, pleased don't hesitate to contact  
mrs. Ginevra Delfini either by phone (+31 70 3394966) or by mail  
(ginevra.delfini@minvrom.nl)

I hope to hear from you soon.

Yours sincerely,  
director for Environmental Safety & Risk Management,



Peter Tofbijn.

**Directoraat-Generaal  
Milieu**  
Directie Risicobeleid  
Straling, Nucleaire en  
Bioveiligheid

**Date**  
February 2, 2009

**Our reference**  
RB/2009010009